American and European researchers publish study in Nature Medicine reporting a new, single treatment option for cystic fibrosis patients
Researchers from the George Washington University (GW), the University of Perugia, and the University of Rome have discovered a potential new drug to treat and stop the progression of cystic fibrosis. Thymosin ?1 (T?1) is a novel therapeutic single molecule-based therapy that not only corrects genetic and tissue defects, but also significantly reduces inflammation seen in cystic fibrosis patients.
“Right now there are multiple treatments for cystic fibrosis, and while these have improved life expectancy dramatically, there is still only a lifespan of about 40 years for patients. No one treatment can stand alone,” said Allan L. Goldstein, Ph.D., co-author of the paper and Professor Emeritus in Residence of Biochemistry and Molecular Medicine at the GW School of Medicine and Health Sciences. “We developed a single treatment that can potentially correct the genetic defect that causes cystic fibrosis and decrease the inflammation that happens as a result.”
Cystic fibrosis is a genetic disease that causes persistent lung infections and limits the ability to breathe over time, and it affects approximately 70,000 worldwide and 30,000 in the U.S. alone. Cystic fibrosis is the result of mutations in the gene encoding the protein called the cystic fibrosis transmembrane conductance regulator (CFTR), which is important to maintain chloride-channel activity affecting the salt and water balance in the lungs. This mutation results in a misfolded CFTR protein, and its premature degradation leads to impaired chloride permeability and persistent lung inflammation.
Goldstein and co-authors Luigina Romani, Ph.D., M.D., at the University of Perugia and Enrico Garaci, M.D., at the University of Rome “San Raffaele,” both in Italy, published their results in Nature Medicine. They report that T?1, a synthetic version of a naturally occurring peptide first isolated from the thymus, corrects the multiple tissue defects found in the lungs and small intestines in a mouse model of cystic fibrosis, as well as the defects in the CFTR seen in cells isolated from cystic fibrosis patients. T?1 not only significantly reduces the inflammation seen in cystic fibrosis, but also increases CFTR maturation, stability, and activity. Due to this two-pronged action, T?1 offers a strong potential to be a single-molecule therapeutic agent to treat and stop the progression of cystic fibrosis.
Goldstein and colleagues first isolated and characterized T?1 as a biological response modifier with potent immune therapeutic activity in 1979. This research was done in large part at GW. Although the peptide is produced in small amounts in several peripheral lymphoid and non-lymphoid tissues, the highest concentrations of T?1 are found in the thymus. T?1, whose commercial name is Zadaxin, has been approved for clinical use for over 15 years in 35 countries in the treatment of patients with viral infections, immunodeficiency diseases, malignancies, and HIV/AIDS. Though not currently available in the U.S., it has an excellent safety profile and does not induce the side effects and toxicities commonly associated with most immunomodulatory agents.
The Latest on: Cystic fibrosis
via Google News
The Latest on: Cystic fibrosis
- Trunki designer Rob Law on cystic fibrosis, suitcases and surviving a crisison June 26, 2020 at 8:56 am
Going to the airport is likely a painful reminder for the businessman. Not as many people know that Law was born with cystic fibrosis. The genetic disease affects the lung and digestive system, and ...
- EU Drug Regulator Endorses Vertex's Triple-Combo Cystic Fibrosis Treatmenton June 26, 2020 at 5:04 am
Europe's health regulator said on Friday its panel has recommended approval of Vertex Pharmaceuticals' triple-combination treatment for cystic fibrosis (CF), a deadly disease that causes build-up of ...
- European advisory group backs Vertex's Kaftrio for cystic fibrosison June 26, 2020 at 4:21 am
The European Medicines Agency's advisory group, CHMP, has adopted a positive opinion recommending approval of Vertex Pharmaceuticals' (NASDAQ:VRTX) Kaftrio (elexacaftor/tezacaftor/ivacaftor) for the t ...
- Seven-year-old boy's amazing gesture for his step-brother and best friend who has cystic fibrosison June 25, 2020 at 9:07 am
Step-brothers Harris Bloom and Joshua Doyle, both aged seven, are best friends. But the lockdown has been particularly tough for Joshua as he has been shielding with life threatening condition cystic ...
- WNY man to run through every Cattaraugus County town to raise money, awareness for cystic fibrosison June 25, 2020 at 7:53 am
Bradley Poole has cystic fibrosis and plans to run 266 miles in a week to raise money for the Cystic Fibrosis Foundation. His goal is $100,000.
- Remembering Gary Ellis and cystic fibrosis fundraiser BassEye Tournamenton June 24, 2020 at 1:34 pm
The BassEye, a long-time fishing event, has ended with the untimely passing of one of its founders, Capt. Gary Ellis of Islamorada, ...
- Global Cystic Fibrosis Drugs Market Growth Factors, Top Key Players, Industry Size, Share, Types and Application by Regions and Forecast to 2026on June 24, 2020 at 3:34 am
Final Report will add the analysis of the impact of COVID-19 on this industry” Global “Cystic Fibrosis Drugs Market” report presents an in-depth assessment of the Cystic Fibrosis Drugs market dynamics ...
- Vertex and Canada hold talks over cystic fibrosis drug, but a deal for newer medicine remains out of reachon June 18, 2020 at 12:22 pm
The icy relationship between Vertex and the Canadian government is showing signs of thawing, with the two holding talks over a cystic fibrosis drug.
- CF Foundation Invests up to $14M in Effort to Solve Key Challenges to Gene Delivery in Cystic Fibrosison June 17, 2020 at 4:17 am
Today the Cystic Fibrosis Foundation announced an investment of up to $14 million in 4D Molecular Therapeutics (4DMT) to develop a customized vehicle to deliver a healthy cystic fibrosis transmembrane ...
via Bing News